Research Paper Volume 13, Issue 1 pp 450—459
Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis
Figure 3. Forest plot comparing PFS for talazoparib, olaparib, and TPC.